Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

18.222.197.132
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Oncology

Palbociclib and ganitumab combo shows limited efficacy for relapsed Ewing sarcoma

Posted on

The combination therapy of palbociclib and ganitumab in Ewing sarcoma (EWS) did not demonstrate sufficient therapeutic activity to warrant further investigation, according to a study. However, a subset of patients experienced prolonged stable disease.

-Advertisement-
-Advertisement-

The Phase 2 trial was an open-label, non-randomized study that enrolled patients aged ≥12 years who had confirmed molecular diagnosis of EWS and measurable disease according to RECIST criteria. The treatment regimen consisted of oral palbociclib (125 mg) on Days 1-21 and intravenous ganitumab (18 mg/kg) on Days 1 and 15 of a 28-day cycle. The primary endpoints of the study were objective response (complete or partial) according to RECIST criteria and toxicity assessment using CTCAE.

A total of 10 evaluable patients were enrolled in the study, with a median age of 25.7 years. The median duration of therapy was 2.5 months (ranging from 0.9 to 10.8 months).

There were no complete or partial responders among the patients. However, 3 out of 10 patients experienced stable disease for more than 4 cycles, and 2 patients had stable disease until completion of the planned therapy or study closure. The 6-month progression-free survival rate was 30% (95% CI 1.6% – 58.4%).

Reference
Shulman DS, Merriam P, Choy E, et al. Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Med. 2023 Jun 12. doi: 10.1002/cam4.6208. Epub ahead of print. PMID: 37306107.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-